Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135

References

• Swartz MN. Bacterial meningitis – a view of the past 90 years. N. Engl. J. Med.351, 1826–1828 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenstein NE, Perkins BA, Stephens DS et al. Meningococcal disease. N. Engl. J. Med.344(18), 1378–1388 (2001).
   PubMed Web of Science ®Google Scholar
• Kaplan SL. Multicenter paediatric surveillance of invasive meningococcal disease. Presented at: Pediatric Academic Societies Annual Meeting, CA, USA, May 2004.
   Google Scholar
• Thompson MJ, Ninis N, Perera R et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet367(9508), 397–403 (2006).
   PubMed Web of Science ®Google Scholar
• Bugden SA, Coles C, Mills GD. The potential role of proclamation in the emergency department management of febrile young adults during a sustained meningococcal epidemic. Emerg. Med. Australas.16, 114–119 (2004).
   PubMedGoogle Scholar
• Odetola FO and Bratton SL. Characteristics and immediate outcome of childhood meningitis treated in the pediatric intensive care unit. Intensive Care Med.31(1), 92–97 (2005).
   Google Scholar
• Booy R, Habibi P, Nadel S et al; and the Meningococcal Research Group. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch. Dis. Child.85, 386–390 (2001).
   PubMed Web of Science ®Google Scholar
• Van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N. Engl. J. Med.351(18), 1849–1859 (2004).
   PubMed Web of Science ®Google Scholar
• Ehrlich TR, von Rosenstiel IA, Grootenhuis MA, Gerrits AI, Bos AP. Long-term psychological distress in parents of child survivors of severe meningococcal disease. Pediatr. Rehabil.8(3), 220–224 (2005).
   Google Scholar
• Rainbow J, Cebelinski E, Bartkus J, Glennen A, Boxrud D, Lynfield R. Rifampin-resistant meningococcal disease. Emerg. Infect. Dis.11(6), 977–979 (2005).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989–1991. MMWR CDC Surveill. Summ.42(2), 21–30 (1993).
   PubMedGoogle Scholar
• Harrison LH, Pass MA, Mendelsohn AB et al. Invasive meningococcal disease in adolescents and young adults. JAMA286(6), 694–699 (2001).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol. Infect.20, 1–11 (2005).
   Google Scholar
• Bruce MG, Rosenstein NE, Capparella JM et al. Risk factors for meningococcal disease in college students. JAMA286(6), 688–693 (2001).
   PubMed Web of Science ®Google Scholar
• Neal KR, Nguyen-Van Tam JS, Jeffrey N et al. Invasive meningococcal disease among university undergraduates: association with universities providing relatively large amounts of catered hall accommodation. Epidemiol. Infect.122(3), 351–357 (1999).
   PubMed Web of Science ®Google Scholar
• Ahmed QA, Arabi YM, Memish ZA. Health risks at the Hajj. Lancet367, 1008–1015 (2006).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A. Meningococcal disease in international travel: vaccine strategies. J. Travel Med.12(Suppl 1), S22–S29 (2005).
   Google Scholar
• Van Gils EJ, van Woensel JB, van der Ende A, Kuijpers TW. Increased attack rate of meningococcal disease in children with a pregnant mother. Pediatrics115, 590–593 (2005).
   Google Scholar
• Rosenstein NE, Perkins BA, Stephens DS et al. The changing epidemiology of meningococcal disease in the United States. J. Infect. Dis.180, 1894–1901 (1999).
   PubMed Web of Science ®Google Scholar
• Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR54(RR-7), 1–21 (2005).
   PubMedGoogle Scholar
• Meningococcal vaccine (2005). Retrieved February 14, 2006, from Health Canada Web site: www.hc-sc.gc.ca/iyh-vsv/med/mening_e.html.
   Google Scholar
• Tikhomirov E, Santamaria M, Esteves K. Meningococcal disease: public health burden and control. World Health Stat. Q.50, 170–177 (1997).
   PubMedGoogle Scholar
• Ninis N, Phillips C, Bailey L et al. The role of healthcare delivery in the outcome of meningococcal disease in children: case-control study of fatal and non-fatal cases. Br. Med. J.330, 1475–1478 (2005).
   PubMed Web of Science ®Google Scholar
• Muros-Le Rouzic E, Guyot F, Doemland M, Teyssou R. Geographical differences in invasive meningococcal disease rates and serogroup distribution. In: Canadian Public Health Association’s 96th Annual Conference, September 18–21, ON, Canada (2005).
   Google Scholar
• Muros-Le Rouzic E, Doemland M, Gilmet G, Teyssou R. Geographical differences in invasive meningococcal disease rates and serogroup distribution. In: Eighth EMGM Meeting, September 7–9, Dublin, Ireland (2005).
   Google Scholar
• Connolly M, Noah N. Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993–6. European Meningitis Surveillance Group. Epidemiol. Infect.122(1), 41–49 (1999).
   PubMed Web of Science ®Google Scholar
• Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr. Infect. Dis. J.23, S274–S279 (2004).
   PubMedGoogle Scholar
• Biebl A, Hartmann G, Bernhard C et al. Vaccine strategies of meningococcal disease: results of a 10-year population-based study. Eur. J. Ped.164(12), 735–740 (2005).
   PubMedGoogle Scholar
• Moura AS, Pablos-Mendez A, Layton M, Weiss D. Epidemiology of meningococcal disease, New York City, 1989–2000. Emerg. Infect. Dis.9(3), 355–361 (2003).
   PubMedGoogle Scholar
• Yazdankhah SP, Kriz P, Tzanakaki G et al. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J. Clin. Microbiol.42(11), 5146–5153 (2004).
   PubMed Web of Science ®Google Scholar
• Gold R. Epidemiology of meningococcal disease in light of recent Hajj-associated outbreaks. Clin. Infect. Dis.36(6), 684–686 (2003).
   PubMedGoogle Scholar
• Tsang RS, Squires SG, Tam TW. Characterization of Neisseria meningitidis strains isolated from invasive meningococcal disease cases in Canada in 2001. Can. J. Microbiol.49(10), 633–638 (2003).
   Google Scholar
• Nicolas P, Ait M’barek N, Al-Awaidy S et al. Pharyngeal carriage of serogroup W135 Neisseria meningitidis in Hajjees and their family contacts in Morocco, Oman and Sudan. APMIS113(3), 182–186 (2005).
   PubMed Web of Science ®Google Scholar
• Njanpop-Lafourcade BM, Parent du Chatelet I, Sanou O, Alonso JM, Taha MK. The establishment of Neisseria meningitidis serogroup W135 of the clonal complex ET-37/ST-11 as an epidemic clone and the persistence of serogroup A isolates in Burkina Faso. Microbes Infect.7(4), 645–649 (2005). Epub (2005).
   PubMed Web of Science ®Google Scholar
• Taha MK, Achtman M, Alonso JM et al. Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet356(9248), 2159 (2000).
   PubMed Web of Science ®Google Scholar
• New Zealand Ministry of Health (2004). Frequently asked questions: meningococcal disease in New Zealand. Retrieved February 13, 2006, from www.moh.govt.nz/moh.nsf/f872666357c511eb4c25666d000c8888/d15a2a1457c9f4834c256a9b00042a70?OpenDocument.
   Google Scholar
• Granoff DM, Forrest B, Rappuoli R. Meningococcal polysaccharide-protein conjugate vaccines. Int. J. Infect. Dis.1(3), 152–157 (1997).
   Google Scholar
• Holst J, Feiring B, Naess LM, Norheim G et al. The concept of “tailor-made”, protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine23, 2202–2205 (2005).
   PubMed Web of Science ®Google Scholar
• Thornton V, Lennon D, Rasanathan K et al. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine24(9), 1395–1400 (2006).
   PubMedGoogle Scholar
• Bjune G, Hoiby EA, Gronnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338(8775), 1093–1096 (1991).
   PubMed Web of Science ®Google Scholar
• Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann.14(2), 195–207, discussion 208–210 (1991).
   PubMedGoogle Scholar
• Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA281(16), 1520–1527 (1999).
   PubMed Web of Science ®Google Scholar
• Holst J, Feiring B, Fuglesang JE et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroups B disease. Vaccine21, 734–737 (2003).
   PubMed Web of Science ®Google Scholar
• Brundage JF, Ryan MA, Feighner BH et al. Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964–1998. Clin. Infect. Dis.35(11), 1376–1381 (2002).
   PubMed Web of Science ®Google Scholar
• Granoff DM, Gupta RK, Belshe RB et al. Induction of immune refractoriness in adults by meningococcal C polysaccharide vaccination. J. Infect. Dis.178(3), 870–874 (1998).
   PubMed Web of Science ®Google Scholar
• Jokhdar H, Borrow R, Sultan Abdulrazaq et al. Immune hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin. Diagn. Lab. Immunol.11, 83–88 (2004).
   PubMedGoogle Scholar
• MacLennan J, Obaro S, Deeks J et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine17, 3086–3093 (1999).
   PubMed Web of Science ®Google Scholar
• De Wals P, Deceuninck G, Boulianne N, De Serres G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA292(20), 2491–2494 (2004).
   PubMed Web of Science ®Google Scholar
• MacLennan J, Obaro S, Deeks J et al. Immune memory 5 years after meningococcal A/C conjugate vaccination in infancy. J. Infect. Dis.183(1), 97–104 (2001).
   PubMed Web of Science ®Google Scholar
• Borrow R, Goldblatt D, Andrews N et al. Antibody persistence and immuneal memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J. Infect. Dis.186, 1353–1357 (2002).
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Borrow R, Miller E. Natural and vaccine-induced immunity and immune memory to Neisseria meningitidis serogroup C in young adults. J. Infect. Dis.185, 397–400 (2002).
   PubMed Web of Science ®Google Scholar
• Maiden MCJ, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet359, 1829–1830 (2002).
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunization campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine20, S58–S67 (2002).
   Google Scholar
• Ramsay Me, Andrews NJ, Trotter CL et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Br. Med. J.326(7385), 365–366 (2003).
   PubMed Web of Science ®Google Scholar
• De Wals P, Erickson L. Economic analysis of the 1992–1993 mass immunization campaign against serogroup C meningococcal disease in Quebec. Vaccine20(21–22), 2840–2844 (2002).
   PubMed Web of Science ®Google Scholar
• Larrauri A, Cano R, Garcia M, de Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine23, 4097–4100 (2005).
   PubMed Web of Science ®Google Scholar
• De Schrijver K, Maes I. An outbreak of serogroups C meningococcal disease in the province of Antwerp (Belgium) in 2001–2002. Eur J Epidemiol.18, 1073–1037 (2003).
   Google Scholar
• Mooney JK, Christie P, Robertson C, Clarke SC. The impact of meningococcal serogroups C conjugate vaccine in Scotland. Clin. Infect. Dis.39, 349–356 (2004).
   Google Scholar
• ZimmerSM, Stephens DS. Meningococcal conjugate vaccines. Expert Opin. Pharmacother.5(4), 855–863 (2004).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet364(9431), 365–367 (2004).
   PubMed Web of Science ®Google Scholar
• Snape MD, Pollard AJ. Meningococcal polysaccharide–protein conjugate vaccines. Lancet Infect. Dis.5, 21–30 (2005).
   PubMed Web of Science ®Google Scholar
• Frasch CE. Recent developments in Neisseria meningitidis group A conjugate vaccines. Expert Opin. Biol. Ther.5(2), 273–280 (2005).
   PubMed Web of Science ®Google Scholar
• Chippaux JP, Garba A, Ethevenaux C et al. Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger. Vaccine22(25–26), 3303–3311 (2004).
   PubMed Web of Science ®Google Scholar
• Pichichero ME Meningococcal conjugate vaccines. Expert Opin. Biol. Ther.5(11), 1475–1489 (2005).
   PubMed Web of Science ®Google Scholar
• Balmer P, Borrow R. Serologic correlates of protection for evaluating the response to meningococcal vaccines. Expert Rev. Vaccines3(1), 77–87 (2004).
   PubMedGoogle Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol.10(5), 780–786 (2003).
   PubMedGoogle Scholar
• Jodar L, Cartwright K, Feavers IM. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biologicals28, 193–197 (2000).
   PubMedGoogle Scholar
• Borrow R, Balmer R, Miller E. Meningococcal surrogates of protection – serum bactericidal antibody activity. Vaccine23, 2222–2227 (2005).
   PubMed Web of Science ®Google Scholar
• Keyserling H, Papa T, Koranyi K et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch. Pediatr. Adolesc. Med.159, 907–913 (2005).
   PubMed Web of Science ®Google Scholar
• Campbell JD, Edelman R, King JC Jr, Papa T, Ryall R, Rennels M. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria conjugate vaccine given to healthy adults. J. Infect. Dis.186, 1848–1851 (2002).
   PubMed Web of Science ®Google Scholar
• Papa T, Bybel MJ, Ryall R, Gilmet G. Safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal diphtheria-polysaccharide conjugate vaccine (MCV-4): Comparison with quadrivalent polysaccharide vaccine (PSV-4). In: 9th Conference of the International Society of Travel Medicine, May 1–5, Lisbon, Portugal. Abstract PO02.13 (2005).
   Google Scholar
• Greenberg DP, Bybel MJ, Papa T, Ryall R. Safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide diphtheria toxoid conjugate vaccine (MCV-4): concomitant administration with typhoid fever (TyphimVi) vaccine. In: 9th Conference of the International Society of Travel Medicine, May 1–5, Lisbon, Portugal. Abstract FC05.05 (2005).
   Google Scholar
• Keyserling H, Rothstein E, Blatter M, Ryall R, Bybel M, Papa T. Augmentation of the immune response to a quadrivalent meningococcal (A, C, Y, W-135) diphtheria conjugate vaccine (MCV-4) by co-administration with tetanus-diphtheria vaccine (td) in healthy adolescents. In: Infectious Disease Society of America 4 2nd Annual Meeting, September 20 –October 4, Boston, Massachusetts. Abstract number 1044 (2005).
   Google Scholar
• Rennels M, King J Jr, Ryall R, Papa T, Froeschle J. Dose escalation, safety and immunogenicity study of four dosages of tetravalent meningococcal polysaccharide diphtheria conjugate vaccine in infants. Pediatr. Infect. Dis. J.23, 429–435 (2004).
   PubMed Web of Science ®Google Scholar
• Rennels M, King J Jr, Ryall R et al. Dose escalation, safety and immunogenicity study of a tetravalent meningococcal polysaccharide diphtheria conjugate vaccine in toddlers. Pediatr. Infect. Dis. J.21, 978–979 (2002).
   PubMed Web of Science ®Google Scholar
• Pichichero M, Casey J, Blatter M et al. A comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- ten-year-old children. Pediatr. Infect. Dis. J.24, 57–62 (2005).
   PubMed Web of Science ®Google Scholar
• Lagos R, Papa T, Munoz A, Ryall R, Pina M, Bassily E. Safety and immunogenicity of a meningococcal (groups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine in healthy children aged 2 to 10 years in chile. Hum. Vaccines1(6), 228–231 (2005).
   PubMed Web of Science ®Google Scholar
• Pichichero M, Casey J, Papa T, Ryall R, Bybel M. A single dose of meningococcal (groups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine (menactra) induces immune memory in young children. Presented at: Canadian Public Health Association’s 96th Annual Conference, September 18–21, Ottawa, Ontario, Canada (2005).
   Google Scholar
• Bashir HE, Heath PT, Papa T et al. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine. Vaccine24(14), 2544–2549 (2006).
   Google Scholar
• Granoff DM, Morgan A, Welsch J. Immunogenicity of an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine in 2-year-old children. Vaccine23, 4307–4314 (2005).
   PubMedGoogle Scholar
• Granoff DM, Morgan A, Welsch J. Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr. Infect. Dis. J.24, 132–136 (2005).
   PubMed Web of Science ®Google Scholar
• Welsch J, Granoff D. Naturally acquired passive protective activity against Neisseria meningitidis group C in the absence of serum bactericidal activity. Infect. Immunol.72(10), 5903–5939 (2004).
   PubMedGoogle Scholar
• Amir J, Louie L, Granoff DM. Naturally-acquired immunity to Neisseria meningitidis group A. Vaccine23, 977–983 (2005).
   PubMedGoogle Scholar
• Harris SL, Finn A, Granoff DM. Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine. Infect. Immun.71(6), 3402–3408 (2003).
   PubMedGoogle Scholar
• Vu DM, Welsch JA, Zuno-Mitchell P, Dela Cruz JV, Granoff DM. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J. Infect. Dis.193(6), 821–828 (2006).
   PubMed Web of Science ®Google Scholar
• Papa T, Veitch K, Gilmet G et al. Safety and Reactogenicity of Menactra in Prelicensure Studies in Children, Adolescents, and Adults. Presented at: 2005 Meningitis Research Foundation Conference, November 23–24, London, UK (2005).
   Google Scholar
• Centers for Disease Control and Prevention. Guillain-Barre syndrome among recipients of MCV-4 meningococcal conjugate vaccine – United States, June-July 2005. MMWR. (2005).
   Google Scholar
• Centers for Disease Control and Prevention. Update: Guillain–Barre syndrome among recipients of Menactra™ meningococcal conjugate vaccine—United States October 2005–February 2006. MMWR55, 364–366 (2006).
   Google Scholar
• Southern J, Deane S, Ashton L et al. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin. Diagn. Lab. Immunol.11(6), 1100–1104 (2004).
   PubMedGoogle Scholar
• Chippaux JP, Garba A, Ethevenaux C et al. Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger. Vaccine22(25–26), 3303–3311 (2004).
   PubMed Web of Science ®Google Scholar
• Borrow R, Goldblatt D, Andrews N, Richmond P, Southern J, Miller E. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J. Infect. Dis.184(3), 377–380 (2001) (Epub 2001).
   PubMed Web of Science ®Google Scholar
• Zhang Q, Lakshman R, Burkinshaw R et al. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom. Infect. Immun.69(7), 4337–4341 (2001).
   PubMed Web of Science ®Google Scholar
• Borrow R, Joseph H, Andrews N et al. Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults. Vaccine19(9–10), 1129–1132 (2000).
   PubMedGoogle Scholar
• MacDonald NE, Halperin SA, Law BJ, Danzig LE, Granoff DM. Can meningococcal C conjugate vaccine overcome immune hyporesponsiveness induced by previous administration of plain polysaccharide vaccine? JAMA283(14), 1826–1827 (2000).
   PubMed Web of Science ®Google Scholar
• Richmond P, Kaczmarski E, Borrow R et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J. Infect. Dis.181(2), 761–764 (2000).
   PubMed Web of Science ®Google Scholar
• Rubinstein LJ, Garcia-Ojeda PA, Michon F, Jennings HJ, Stein KE. Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine. Infect. Immun.66(11), 5450–5456 (1998).
   Web of Science ®Google Scholar
• Lett E, Gangloff S, Zimmermann M, Wachsmann D, Klein JP. Immunogenicity of polysaccharides conjugated to peptides containing T- and B-cell epitopes. Infect. Immun.62(3), 785–792 (1994).
   Google Scholar
• Amir J, Louie L, Granoff DM. Naturally-acquired immunity to Neisseria meningitidis group A. Vaccine23(8), 977–983 (2005).
   PubMedGoogle Scholar
• Guttormsen HK, Bjerknes R, Halstensen A, Naess A, Hoiby EA, Solberg CO. Cross-reacting serum opsonins to meningococci after vaccination. J. Infect. Dis.167(6), 1314–1319 (1993).
   Google Scholar
• Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J. Med. Microbiol.53(Pt 9), 821–832 (2004).
   PubMed Web of Science ®Google Scholar
• deWals P, Trottier P, Pepin J. Relative efficacay of different immunization schedules for the prevention of serogroup C emningococcal disease. Vaccine24, 3500–3504 (2006).
   Google Scholar
• Welte R, Dobbelsteen GV, Bos JM et al. Ecomonic evaluation of meningococcal serogroup C conjugate vaccinnation programmes in the netherlands. Vaccine23, 470–479 (2004).
   PubMed Web of Science ®Google Scholar